-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
NETs: Casting a new light on sepsis management – presentation
- Share
- Tweet
- Share on Facebook
- Share
Volition hosted a symposium at ESICM Lives 2024 titled NETs: Casting a new light on sepsis management. During the session, experts presented findings from large, independent studies regarding the potential clinical utility of Nu.Q® NETs to enhance sepsis management.
Chaired by Professor Djillali Annane, session speakers included Dr Andrew Retter, Dr Caroline Neumann of Jena University Hospital and Dr Terry Kelly.
You can download the symposium presentation below.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields